Regeneus Ltd Stock Market Press Releases and Company Profile
Quarterly Report
Quarterly Report

Sydney, April 26, 2018 AEST (ABN Newswire) - Regeneus Ltd (googlechartASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.

The financial highlights for the quarterly reporting period include:

- Net cash outflow $1.70 million, consistent with prior quarters; and
- Agreement was reached with Paddington St Finance Pty Limited to provide a facility that forward funds, via a loan, up to 80% of the Company's research and development tax incentive for FY18. Currently, the forecast loan funds available would be between $1.9 million and $2.0 million.

Cash position at 31 March is $1.70 million which in conjunction with the loan facility should provide adequate funding until the next milestone payment due as part of the Progenza licence agreement with Asahi Glass Co Ltd of Japan.

The sources of funding for the Company over the next 18 months include: milestone payments and potential clinical licensing opportunities for Progenza; shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013; the R&D tax incentive for FY'18 including forward funding arrangements where necessary and options exercised. These sources of cash should ensure that the company has sufficient funding to support its R&D, clinical trials and operating activities for FY' 18 and into FY'19.

Further licensing opportunities may provide additional funding for incremental activities.

To view the full report, please visit:
http://abnnewswire.net/lnk/1I41B90D


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

https://plus.google.com/108721050557390681250 https://twitter.com/Regeneus https://www.facebook.com/pages/Regeneus/110433905646491 https://www.youtube.com/user/Regeneus http://www.linkedin.com/company/regeneus-ltd?trk=top_nav_home abnnewswire.com 


Contact

Regeneus Ltd
T: +61-2-9499-8010
E: info@regeneus.com.au
WWW: www.regeneus.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 28) (Since Published: 6300)